Highlighted Articles

Highlighted Articles
Veröffentlicht: (2024)

Highlighted Articles
Veröffentlicht: (2024)

Highlights
Veröffentlicht: (2024)

Highlights
Veröffentlicht: (2024)

Highlights
Veröffentlicht: (2024)

Highlights
Veröffentlicht: (2024)

US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
von: Kimberly A. Smith, et al.
Veröffentlicht: (2025)

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes
von: Ola Nordqvist, et al.
Veröffentlicht: (2025)

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
von: Shin‐Yi Lin, et al.
Veröffentlicht: (2025)

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV : An Emerging Frontier for Clinical Pharmacology
von: Aaron S. Devanathan, et al.
Veröffentlicht: (2025)

Predicting OCT2 / MATEs ‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)
von: Satoshi Asano, et al.
Veröffentlicht: (2025)

What African Patients, Clinicians, and Regulators Can Gain from Pharmacometrics: Forecasts for the Future in a New Era in Health
von: Steven E. Kern
Veröffentlicht: (2025)

History and Evolution of Innovations in Clinical Pharmacology
von: Lawrence J. Lesko, et al.
Veröffentlicht: (2025)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
von: Patrick J. Arena, et al.
Veröffentlicht: (2025)

A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition
von: Sheetal K. Panday, et al.
Veröffentlicht: (2025)

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
von: Polly Paul, et al.
Veröffentlicht: (2025)

Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel‐Treated Participants
von: Luis Ortega‐Paz, et al.
Veröffentlicht: (2025)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
von: Yue Zhu, et al.
Veröffentlicht: (2025)

Planning Post‐Launch Evidence Generation: Lessons From France, England and Spain
von: Seamus Kent, et al.
Veröffentlicht: (2025)

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP
von: Munjal Patel, et al.
Veröffentlicht: (2025)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
von: Lukas K. van Vugt, et al.
Veröffentlicht: (2025)

Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
von: Ting Wang, et al.
Veröffentlicht: (2025)

Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
von: Bridget M. Nugent, et al.
Veröffentlicht: (2025)

Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
von: Gabriel K. Innes, et al.
Veröffentlicht: (2025)

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
von: Catherine Chanfreau‐Coffinier, et al.
Veröffentlicht: (2025)

In This Issue
Veröffentlicht: (2025)

Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial
von: Enora Laas, et al.
Veröffentlicht: (2025)

Leading the Way: Multi‐Drug Resistance Protein (MDR1) and Clinical Pharmacology—Commentary on Kim et al.
von: Kathleen M. Giacomini
Veröffentlicht: (2025)

Issue Information
Veröffentlicht: (2025)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
von: Gerald Chun‐To So, et al.
Veröffentlicht: (2025)

Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials
von: Guotao Chu, et al.
Veröffentlicht: (2025)

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
von: James M. Stevenson, et al.
Veröffentlicht: (2025)

Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations
von: Rashudy F. Mahomedradja, et al.
Veröffentlicht: (2025)

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
von: Gianmario Candore, et al.
Veröffentlicht: (2025)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
von: Aurélie Cabannes‐Hamy, et al.
Veröffentlicht: (2025)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
von: Weihua Jiang, et al.
Veröffentlicht: (2025)